TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Instagram Outage Disrupts Thousands of U.S. Users 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
NEW YORK, May 03, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Friday May 5, 2017 at 8:30am ET to discuss results for the first quarter of 2017 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.
To participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter 2017 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX-G
Contact Jenna Bosco Vice President, Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]
